Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.58 |
| ▸ | DAO | P14920 | 2/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.56 |
| ▸ | DDO | Q99489 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.53 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.50 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29855487 | 1.00 | CYP2A6 (0.58) | CYP2A6DAOBRD4DDOKDR | |
| SCHEMBL31018786 | 0.83 | DAO (0.55) | CYP2A6DAOBRD4DDOKDR | |
| SCHEMBL8604094 | 0.83 | DAO (0.55) | CYP2A6DAOBRD4DDOKDR | |
| SCHEMBL31018784 | 0.80 | DAO (0.51) | CYP2A6DAOBRD4DDOKDR | |
| SCHEMBL15796663 | 0.79 | DPYD (0.53) | CYP2A6DAOBRD4DDOKDR | |
| SCHEMBL4106429 | 0.77 | DAO (0.60) | DAODDOKDM4EPDGFRBFLT3 | |
| SCHEMBL13664826 | 0.77 | CYP2A6 (0.44) | CYP2A6KDRCHEK1PDGFRBFGFR1 | |
| SCHEMBL32662081 | 0.77 | DAO (0.60) | DAODDOKDM4EFLT3GRIA1 | |
| SCHEMBL17603437 | 0.77 | DAO (0.60) | DAOGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL17601383 | 0.77 | DAO (0.60) | DAOGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105601630-A | Synthesizing method for 6-oxo-13H-substitued benzo [b] quinoline [3,4-f][1,4] diazepine compound | CHINA NAT ANALYTICAL CENTER GUANGZHOU | 2016-05-25 | — | — | CN | claimed |
| CN-1958572-A | Compound in category of dihydro quinolines, preparation method, and composition of medication | SHANGHAI INST OF MEDICINE C A (CN) | 2007-05-09 | — | — | CN | claimed |
| US-20250129045-A1 | SMALL MOLECULE PIM AND MTOR KINASE INHIBITOR AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-04-24 | — | — | US | disclosed |
| US-20240417377-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING ß-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | SYMBERIX, INC. | 2024-12-19 | — | — | US | disclosed |
| US-12102631-B2 | Quinolylnitrones for the treatment and prevention of a cerebral stroke or ischaemia | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2024-10-01 | — | — | US | disclosed |
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-08-29 | — | — | US | disclosed |
| US-12017994-B2 | Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea | SYMBERIX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-4362978-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20230365540-A1 | SMALL MOLECULE INHIBITORS OF ENPP1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-16 | — | — | US | disclosed |
| US-20230365540-A1 | SMALL MOLECULE INHIBITORS OF ENPP1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-16 | — | — | US | disclosed |
| US-20230365540-A1 | SMALL MOLECULE INHIBITORS OF ENPP1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-16 | — | — | US | disclosed |
| US-5089495-A | Lipoxygenase inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (FR) | 1992-02-18 | — | — | US | disclosed |
| US-4971970-A | BACTERICIDES, FORMYL-4-OXOQUINOLINES | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1990-11-20 | — | — | US | disclosed |
| CN-1046903-A | Process for preparing heterocyclic ether derivatives | ICI PLC (GB) | 1990-11-14 | — | — | CN | disclosed |
| EP-0385662-A2 | Heterocycles with inhibitory activity of 5-lipoxygenase | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0385680-A2 | Heterocyclic ethers as 5-lipoxygenase inhibitors | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0381375-A1 | Heterocyclic derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-08-08 | — | — | EP | disclosed |
| US-4578381-A | ANTIULCER AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-03-25 | — | — | US | disclosed |
| US-4390541-A | ANTIALLERGENS; ANTISPASMODIC AGENTS | LILLY INDUSTRIES LIMITED (GB) | 1983-06-28 | — | — | US | disclosed |
| EP-0055068-A1 | Quinolone derivatives and their use as pharmaceuticals | Lilly Industries Limited (GB) | 1982-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12102631-B2 | Quinolylnitrones for the treatment and prevention of a cerebral stroke or ischaemia | NLN, TXN2, TXN | CYP2A6 4159/4885DAO 629/4885BRD4 1797/4885 |
| US-20240417377-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING ß-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | GUSB, SI, ENGASE | CYP2A6 220/4885DAO 705/4885BRD4 2474/4885 |
| US-12017994-B2 | Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea | GUSB, SI, ENGASE | CYP2A6 245/4885DAO 723/4885BRD4 2477/4885 |
| US-20250129045-A1 | SMALL MOLECULE PIM AND MTOR KINASE INHIBITOR AND METHODS OF USE THEREOF | PIM3, PIM1, PIM2 | CYP2A6 4784/4885DAO 3657/4885BRD4 376/4885 |
| US-20230365540-A1 | SMALL MOLECULE INHIBITORS OF ENPP1 | ENPP1, ENPP2, ENPP3 | CYP2A6 4523/4885DAO 4259/4885BRD4 2356/4885 |
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL1RN | CYP2A6 2406/4885DAO 3519/4885BRD4 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.